Harmony Biosciences Holdings, Inc.
$1.85B- Market cap
- $2.46B
- Debt
- +$163.66M
- Cash
- −$775.34M
Capital structure 94% equity / 6% debt · EV / Revenue 2.13x · EV / EBITDA 7.28x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: HRMY stock price at discount vs WWD $42.27 current versus $130.51 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at WWD's multiple
Implied fair value · at HRMY's multiple
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Multiple discount
Value edge
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: HRMY FY 2025 (ended Dec 31, 2025) · WWD FY 2025 (ended Sep 30, 2025). Fiscal years are not aligned.
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 94% equity / 6% debt · EV / Revenue 2.13x · EV / EBITDA 7.28x
Capital structure 97% equity / 3% debt · EV / Revenue 5.84x · EV / EBITDA 29.08x
WWD carries the larger enterprise value at $20.82B against $1.85B; HRMY trades on the lower EV / Revenue multiple (2.13x vs 5.84x); HRMY on the lower EV / EBITDA (7.28x vs 29.08x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
HARMONY BIOSCIENCES HOLDINGS, INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
WOODWARD, INC. · implied price per share
Bear
$58.31
Base
$70.91
Bull
$87.91
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.19x
0.27x
Net debt / EBITDA
Leverage against operating earnings
-2.41x
0.52x
Cash and equivalents
Liquid reserves on the balance sheet
$775.34M
$327.43M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Jazz Pharmaceuticals plc
HRMY vs JAZZ
SUPERNUS PHARMACEUTICALS, INC.
HRMY vs SUPN
Intra-Cellular Therapies, Inc.
HRMY vs ITCI
ACADIA PHARMACEUTICALS INC
HRMY vs ACAD
Vanda Pharmaceuticals Inc.
HRMY vs VNDA
LivaNova PLC
HRMY vs LIVN
HEXCEL CORP /DE/
HRMY vs HXL
Parker-Hannifin Corp
HRMY vs PH
Eaton Corp plc
HRMY vs ETN
RTX Corp
HRMY vs RTX
CURTISS WRIGHT CORP
HRMY vs CW
$163.66M
$702.84M
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe HRMY’s higher growth and much stronger margins deserve a valuation closer to WWD’s WWD-based framework, then the current price looks attractive because HRMY is trading near its historical and DCF lows while WWD-implied valuation is far higher.
HRMY trades at a large valuation discount to WWD despite stronger operating metrics, with a P/E of 13.7x versus 58.1x, P/S of 2.5x versus 7.0x, and EV/EBITDA of 5.6x versus 35.3x. The implied price of $157.56 is far above both the current price of $37.26 and HRMY’s own historical band and DCF range, suggesting WWD multiple approach may be overstating fair value.
Supporting Metrics